Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cabazitaxel

FDA-approved product (solution, intravenous), marketed as Cabazitaxel, Jevtana Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cabazitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cabazitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cabazitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)

    NCT03050866 · start 2017-02-21

    Registered record
    Registry ID
    NCT03050866
    Conditions
    Circulating Tumor Cell; Metastatic Prostate Cancer
    Interventions
    Cabazitaxel; Antihistamine; Corticosteroid; H2 antagonist; Antiemetic
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-02-21
    Completion
    2022-08-19
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirculating Tumor Cell; Metastatic Prostate Cancer
    InterventionCabazitaxel; Antihistamine; Corticosteroid; H2 antagonist +1 more
    PhasePhase 2
    Registry statusUnknown

  • Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT02703623 · start 2016-05-18

    Registered record
    Registry ID
    NCT02703623
    Conditions
    Castration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression; Stage IV Prostate Adenocarcinoma AJCC v7
    Interventions
    Abiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin; Ipilimumab; Laboratory Biomarker Analysis; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-05-18
    Completion
    2028-03-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration Levels of Testosterone; Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; PSA Progression +1 more
    InterventionAbiraterone Acetate; Apalutamide; Cabazitaxel; Carboplatin +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs

    NCT02621190 · start 2016-02

    Registered record
    Registry ID
    NCT02621190
    Conditions
    Prostatic Neoplasms
    Interventions
    cabazitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2016-02
    Completion
    2019-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    Interventioncabazitaxel
    PhasePhase 2
    Registry statusWithdrawn

  • Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer

    NCT02512458 · start 2015-10-29

    Registered record
    Registry ID
    NCT02512458
    Conditions
    Bone Metastatic Prostate Cancer
    Interventions
    Cabazitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10-29
    Completion
    2019-12-27
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Metastatic Prostate Cancer
    InterventionCabazitaxel
    PhasePhase 2
    Registry statusCompleted

  • Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

    NCT02522715 · start 2015-08-13

    Registered record
    Registry ID
    NCT02522715
    Conditions
    Castration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v7
    Interventions
    Cabazitaxel; Enzalutamide; Laboratory Biomarker Analysis; Pharmacological Study; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-13
    Completion
    2027-01-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Resistant Prostate Carcinoma; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v7
    InterventionCabazitaxel; Enzalutamide; Laboratory Biomarker Analysis; Pharmacological Study +1 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

    NCT02379390 · start 2015-06-17

    Registered record
    Registry ID
    NCT02379390
    Conditions
    Prostate Cancer Metastatic
    Interventions
    Cabazitaxel XRP6258; Ezalutamide; Abiraterone acetate; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-06-17
    Completion
    2018-05-10
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    InterventionCabazitaxel XRP6258; Ezalutamide; Abiraterone acetate; Prednisone
    PhasePhase 2
    Registry statusTerminated

  • Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer

    NCT02441894 · start 2015-04

    Registered record
    Registry ID
    NCT02441894
    Conditions
    Prostate Cancer
    Interventions
    CABAZITAXEL XRP6258; PEG-G-CSF; Prednisolone; Dexchlorpheniramine or Diphenhydramine; Ranitidine; Metoclopramide, Granisetron, or Ondansetron; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-04
    Completion
    2016-11
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionCABAZITAXEL XRP6258; PEG-G-CSF; Prednisolone; Dexchlorpheniramine or Diphenhydramine +3 more
    PhasePhase 4
    Registry statusCompleted

  • A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

    NCT03258320 · start 2015-01

    Registered record
    Registry ID
    NCT03258320
    Conditions
    Prostate Cancer Patients
    Interventions
    Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2015-01
    Completion
    2027-12
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Patients
    InterventionCabazitaxel, Docetaxel, Mitoxantrone or Satraplatin
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

    NCT03048942 · start 2014-12-18

    Registered record
    Registry ID
    NCT03048942
    Conditions
    HER2 Negative Metastatic Breast Cancer
    Interventions
    Cabazitaxel; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-12-18
    Completion
    2025-03-19
    Enrolment
    158

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2 Negative Metastatic Breast Cancer
    InterventionCabazitaxel; Paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

    NCT02202772 · start 2014-12-01

    Registered record
    Registry ID
    NCT02202772
    Conditions
    Urothelial Carcinoma of the Urinary Bladder
    Interventions
    Cabazitaxel; Gemcitabine; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2014-12-01
    Completion
    2028-04
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma of the Urinary Bladder
    InterventionCabazitaxel; Gemcitabine; Cisplatin
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer

    NCT02254785 · start 2014-10

    Registered record
    Registry ID
    NCT02254785
    Conditions
    Metastatic Castration-Resistant Prostatic Cancer
    Interventions
    cabazitaxel; Abiraterone; Enzalutamide 160mg daily (oral)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-10
    Completion
    2020-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostatic Cancer
    Interventioncabazitaxel; Abiraterone; Enzalutamide 160mg daily (oral)
    PhasePhase 2
    Registry statusUnknown

  • Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

    NCT02218606 · start 2014-08

    Registered record
    Registry ID
    NCT02218606
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone acetate 1000 mg po daily; Cabazitaxel 25 mg/m2 IV; prednisone 5 mg po BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08
    Completion
    2023-10-13
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone acetate 1000 mg po daily; Cabazitaxel 25 mg/m2 IV; prednisone 5 mg po BID
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC

    NCT01913067 · start 2013-09

    Registered record
    Registry ID
    NCT01913067
    Conditions
    Brain Metastasis; Breast Cancer; Non Small Cell Lung Cancer
    Interventions
    Cabazitaxel; Contrast-enhanced whole brain MRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2013-09
    Completion
    2016-09
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Metastasis; Breast Cancer; Non Small Cell Lung Cancer
    InterventionCabazitaxel; Contrast-enhanced whole brain MRI
    PhasePhase 2
    Registry statusWithdrawn

  • Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment

    NCT02204332 · start 2013-03

    Registered record
    Registry ID
    NCT02204332
    Conditions
    Colorectal Cancer
    Interventions
    Cabazitaxel; Best Supportive Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-03
    Completion
    Not recorded
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionCabazitaxel; Best Supportive Care
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

    NCT01779479 · start 2013-02

    Registered record
    Registry ID
    NCT01779479
    Conditions
    Primary Breast Cancer
    Interventions
    Cabacitaxel; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02
    Completion
    2016-02
    Enrolment
    333

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Breast Cancer
    InterventionCabacitaxel; Paclitaxel
    PhasePhase 2
    Registry statusCompleted